Evidence map›Paper›PMID 42847415›Full record

ArticleEuropean journal of immunology2026

PGE2 Enhances Human ILC3 Function but Constrains ILC2-to-ILC3 Plasticity.

Lorenz Wirth, Whitney Weigel, Efthymia Kokkinou, Johan Kolmert, Anna-Karin Johnsson, Alessandro Quaranta, Craig Wheelock, Mattias Jangard, Ram V Pandey, Sven-Erik Dahlén and 3 more

Abstract read
In one paragraph

Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lorenz WirthCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-4795-7814
Whitney WeigelCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Efthymia KokkinouDepartment of Oncology, Bloomberg Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johan KolmertUnit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0001-7116-6583
Anna-Karin JohnssonDivision of Immunology and Allergy, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-0018-700X
Alessandro QuarantaUnit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-3167-3772
Craig WheelockUnit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-8113-0653
Mattias JangardENT Unit, Sophiahemmet University and Sophiahemmet Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-3772-2026
Ram V PandeyDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Sven-Erik DahlénClinical Lung- and Allergy Research Unit, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-4993-4002
Christopher Andrew TibbittCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-7730-7700
Thomas HochdörferMechanistic Biology & Profiling, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID https://orcid.org/0000-0002-9276-3114
Jenny MjösbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-1119-0976

Funding

European Union's Horizon 2020 research and innovation
6 · The paper itself

Abstract

Type 2 innate lymphoid cells (ILC2) drive eosinophilic asthma, whereas ILC3 and plastic ILC2/3 states are implicated in neutrophilic and mixed granulocytic disease endotypes. While lipid mediators regulate ILC2 function and airway inflammation, their role in human ILC3 biology and ILC plasticity remains poorly defined. We investigated how eicosanoid biosynthesis and signalling regulate human ILC2 and ILC3 function across canonical and plastic states. Here, we identified distinct prostaglandin (PG) profiles across ILC subsets. Unlike ILC2, which produce and rely on PGD

Indexed as

AsthmaCell PlasticityDinoprostoneImmunity, InnateLymphocytesCells, CulturedHumansProstaglandin D2DinoprostoneProstaglandin D2ILC2ILC3PGE2plasticityprostaglandins

Identifiers

PMID42847415
PMCPMC13647482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.